Loading...
Loading...
Cubist Pharmaceuticals, Inc.
CBST and Optimer Pharmaceuticals, Inc.
OPTR today announced the expiration of the waiting period under the
Hart-Scott-Rodino Antitrust Improvements Act of 1976 (“HSR”) in connection
with the previously announced merger agreement under which Cubist will acquire
all of the outstanding common stock of Optimer.
Expiration of the HSR waiting period satisfies one of the conditions to the
closing of the merger. The proposed merger remains subject to approval by the
stockholders of Optimer, as well as other customary closing conditions.
Upon closing of the merger, each holder of Optimer common stock will receive
$10.75 per share in cash, plus one Contingent Value Right, entitling the
holder to receive an additional one-time cash payment of up to $5.00 for each
share they own if certain net sales of DIFICID® (fidaxomicin) in the United
States and Canada are achieved.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in